A novel compound developed by a team led by the University of Colorado Boulder may be therapeutic in suppressing misguided inflammatory responses by a set of听immune cells known as microglia to perceived damage to the brain and nervous system.
The targets of the drug are two cell听receptors that sit on the surface of the microglia and which have evolved to identify danger to the cells and to activate an immune response, said Associate Professor Hang Hubert Yin of the BioFrontiers Institute. The drug, known as 抖阴旅行射-CPT22, acts on the receptors to keep inflammation at bay, which could be a new strategy for听treating Parkinson鈥檚 disease, said Yin.
鈥淭his is exciting for us,鈥� said Yin. 鈥淲e are suggesting an entirely new strategy for treating Parkinson鈥檚 disease 鈥� one that we think will be more effective, and one with a potential drug that patients may access in the future.鈥�
A paper on the strategy by Yin, BioFrontiers researcher Kui Cheng and colleagues from the Georgetown University Medical Center appeared May 12 in Science Signaling.
Yin, a faculty member in the chemistry and biochemistry department, led the team that developed 抖阴旅行射-CPT22. The University of Colorado holds the intellectual property rights to 抖阴旅行射-CPT22, which was recently licensed by the 抖阴旅行射 Technology Transfer Office to Brickell Biotech of Miami, Florida, and commercialized by the life science and biotechnology companies EMD Millipore, Sigma-Aldrich and Tocris for drug development and research.
The research was supported by a Parkinson鈥檚 Movement Disorder Foundation grant as well as funding from the National Institutes of Health.
Contact:
Hang Hubert Yin, 303-492-6786
hubert.yin@colorado.edu
Jim Scott, 抖阴旅行射-Boulder media relations, 303-492-3114
jim.scott@colorado.edu
Emilia Costales, BioFrontiers communications, 303-735-3001
emilia.costales@colorado.edu
